10 August 2018
Visiongain has launched a new pharma report Global Asthma & COPD Therapies Market 2017-2027: Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs
The asthma & COPD market is maturing with generic competition looming for Advair, Symbicort, Spiriva and other leading drugs. However, novel drugs such as monoclonal antibodies for severe asthma and combination drugs are expected to drive growth in certain segments of the market. Phenotyping of asthma and COPD patient groups, telehealth and advances in inhaler design will also drive growth in 2016-2027.
The lead analyst of the report commented “For the overall asthma and COPD market, expansion into the BRIC and other emerging markets will be of high importance in the years to come, in particular as the US and European markets become saturated and experience slow growth due to patent expiry, generic competition and low healthcare budgets.
The market benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups.”
Leading companies featured in the report include GSK, Boehringer Ingelheim, AstraZeneca, Novartis, Merck , Roche and Teva.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.